Followers | 247 |
Posts | 49942 |
Boards Moderated | 51 |
Alias Born | 08/29/2007 |
Sunday, August 06, 2023 11:50:43 AM
Biora Therapeutics Inc NASDAQ: BIOR
GoSymbol lookup
Health Care : Biotechnology | Small Cap ValueCompany profile
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and needle-free delivery of biotherapeutics. The Company's therapeutics pipeline includes two therapeutic delivery platforms: NAVICAP and BIOJET. NAVICAP is a targeted oral delivery platform of therapeutics to the site of disease in the GI tract, designed to improve outcomes for patients with inflammatory bowel disease (IBD). The NAVICAP drug delivery device is an investigational, clinical-stage, single-use ingestible device approximately the size of a fish oil capsule. BIOJET is a systemic oral delivery platform of biotherapeutics designed to replace injection with needle-free, oral delivery of molecules for better management of chronic diseases. The Company's targeted therapeutics pipeline programs include NAVICAP, BT-600 and BT-001. Its systemic therapeutics pipeline programs include BIOJET, BT-200 and BT-002.
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent BIOR News
- Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600 • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/03/2024 08:05:00 PM
- Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 03/26/2024 08:05:00 PM
- U.S. Index Futures on the Rise, Oil Prices Show Stability • IH Market News • 03/26/2024 11:21:42 AM
- Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:11:01 PM
- Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600 • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:05:07 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:43:10 PM
- Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co. • GlobeNewswire Inc. • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 10:20:53 PM
- Biora Therapeutics Provides Outlook for 2024 • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600 • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
- Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/02/2024 05:15:29 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 10:19:36 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/20/2023 09:35:54 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM